HematologyNews.net

Hematology Xagena

XagenaNewsletter
Medical Meeting
Xagena Mappa
Mediexplorer.it

Selinexor ( Xpovio ) is an oral, selective inhibitor of XPO1-mediated nuclear export, leading to the reactivation of tumor suppressor proteins. In a phase 1b/2 study, the combination of once weekl ...


The treatment of relapsed or refractory diffuse large B-cell lymphoma ( R/R DLBCL ) remains challenging. Atezolizumab ( Tecentriq ) and Obinutuzumab ( Gazyvaro ) are monoclonal antibodies acting res ...


Belantamab mafodotin, a B-cell maturation antigen targeting immunoconjugate, has demonstrated clinically meaningful, single-agent activity in patients with heavily pre-treated relapsed / refractory mu ...


Outcomes are poor in triple-class exposed patients with relapsed and refractory multiple myeloma ( RRMM ) who progress on immunomodulatory agents ( IMiDs ), proteasome inhibitors ( PIs ), and CD38 ant ...


JNJ-68284528 ( JNJ-4528 ) is a chimeric antigen receptor T ( CAR-T ) cell therapy containing 2 B-cell maturation antigen ( BCMA)-targeting single-domain antibodies. Researchers have presented updat ...


PD-1 blockade via Pembrolizumab ( Keytruda ) monotherapy has shown antitumor activity in relapsed or refractory classic Hodgkin lymphoma ( R/R cHL ). KEYNOTE-204 was a randomized, international, o ...


B2001X is a multicenter global study of Tisagenlecleucel ( Tisa-cel; Kymriah ) to provide access to patients with relapsed / refractory ( r/r ) acute lymphoblastic leukemia ( ALL ) including prior ant ...


Acalabrutinib ( Calquence ) is a next-generation, highly selective, covalent Bruton tyrosine kinase inhibitor approved for patients with chronic lymphocytic leukemia ( CLL ) including those with relap ...


T cells expressing anti-CD19 chimeric antigen receptors ( CARs ) can cause complete remissions of relapsed lymphoma. The first clinical trial of anti-CD19 CAR T cells was conducted to show respons ...


Immunochemotherapy is standard of care for patients with previously untreated advanced stage follicular lymphoma ( FL ). Four-year data from the phase III GALLIUM study have previously demonstrated ...


Ibrutinib ( Imbruvica ) has shown single-agent activity in relapse / refractory ( R/R ) primary central nervous system lymphoma ( PCNSL ), and the high dose Methotrexate ( HD-MTX ) has been the backbo ...


The safety and efficacy of Ibrutinib ( Imbruvica ), a once-daily Bruton's tyrosine kinase inhibitor, in chronic lymphocytic leukemia / small lymphocytic lymphoma ( CLL/SLL ) was demonstrated in this ...


According to results from a phase I/IIa trial at The University of Texas MD Anderson Cancer Center, treatment with cord blood-derived chimeric antigen receptor ( CAR ) natural killer ( NK )-cell thera ...


Researchers have evaluated early disease progression and its impact on overall survival ( OS ) in previously untreated follicular lymphoma patients in GALLIUM, and investigated the effect on early dis ...


RESONATE-2 is a phase 3 study of first-line Ibrutinib ( Imbruvica ) versus Chlorambucil in chronic lymphocytic leukemia ( CLL ) / small lymphocytic lymphoma ( SLL ). Patients aged greater than or ...